Tag Archives | cardiovascular disease

High Volatility Among Individual stocks with Few Trends…Update-4

Update-4.  4/3 11:45A… Mid and Small Cap biotechs are momentum leaders: XBI hits 2019 high at $92.50. Update-3    4/2/19… Biotechs Outperform Major Market Indices Gene therapy stocks rally big: SGMO 28.96%, VYGR 7.38%, CRSP 6.91%  NTLA 4.9% MGTX up 4.6%, etc. Most Mid-Caps green: BPMC up 2.2%, SRPT up 3.88%, AGIO up 3.41% etc. […]

Continue Reading 0

J.P.Morgan Healthcare Conference: Picks and Trades… Updates GNMK

Update: GenMark (GNMK) Soars on Q4 and Full Year 2018 Results Revenues of $70.8M were 35% over 2017 Results Q4 Revenues were $19.4M an increase of 21% over prior year. ePlex Revenues for Q4 were 412.1M an increase of 110% over prior year. Loss per share was reduced from 26c per share to 21c per […]

Continue Reading 0

Emerging Growth Stocks: Long Ideas in Life Science for 2019…Updates-Risk On…FED on Hold and “Patient”

Update ….Jan 30 2:45p  EST …FED to be Patient and Policy Stance is Appropriate FED to “wait and see” before raising rates-stocks soar. FED-“US Economy in a good place” NASDAQ up 2%, DOW up 1.73%, S&P up 1.53% XLV up 1.27%, IBB flat, XBI up 1.72%. Large cap biopharmas trail broad rally: AMGN,BIIB in the […]

Continue Reading 0

AACC Notes: Biomarkers for Cardiovascular Risk-hsCRP

Last week’s Plenary Session from the AACC featured Paul Ridker.MD,MPH from Brigham and Women’s Hospital ,Boston,MA speaking about Inflammation,hsCRP and Cardiovascular Prevention. The session reviewed data from the JUPITER trial for the use of statins in primary cardiovascular prevention. Dr. Ridker believes that the biomarker hsCRP (high sensitivity C-reactive protein) in combination with LDL are […]

Continue Reading 0